164 related articles for article (PubMed ID: 24755125)
1. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men.
van Gelderen M; Tretter R; Meijer J; Dorrepaal C; Gangaram-Panday S; Brooks A; Krauwinkel W; Dickinson J
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):693-701. PubMed ID: 24755125
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
3. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
[TBL] [Abstract][Full Text] [Related]
4. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
Wada N; Iuchi H; Kita M; Hashizume K; Matsumoto S; Kakizaki H
Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study.
Katoh T; Kakizaki H; Lee KS; Ishida K; Katou D; Yamamoto O; Jong JJ; Sumarsono B; Uno S; Yamaguchi O
Low Urin Tract Symptoms; 2021 Jan; 13(1):98-107. PubMed ID: 32975024
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3-period crossover study in healthy Chinese male volunteers.
Chu N; Xu H; Wang G; Wang J; Chen W; Yuan F; Yang M; Li X
Clin Ther; 2015 Feb; 37(2):462-72. PubMed ID: 25465944
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.
Nitti VW; Chapple CR; Walters C; Blauwet MB; Herschorn S; Milsom I; Auerbach S; Radziszewski P
Int J Clin Pract; 2014 Aug; 68(8):972-85. PubMed ID: 24703195
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the effect of mirodenafil on the hemodynamics of healthy male Korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study.
Gu N; Kim J; Lim KS; Shin KH; Kim TE; Lee B; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Sep; 34(9):1929-39. PubMed ID: 22921287
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
Ichihara K; Masumori N; Fukuta F; Tsukamoto T; Iwasawa A; Tanaka Y
J Urol; 2015 Mar; 193(3):921-6. PubMed ID: 25254938
[TBL] [Abstract][Full Text] [Related]
10. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
Chapple CR; Amarenco G; López Aramburu MA; Everaert K; Liehne J; Lucas M; Vik V; Ridder A; Snijder R; Yamaguchi O;
Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females.
Nomura Y; Iitsuka H; Toyoshima J; Kuroishi K; Hatta T; Kaibara A; Katashima M; Moy S; Sawamoto T
Drug Metab Pharmacokinet; 2016 Dec; 31(6):411-416. PubMed ID: 27829538
[TBL] [Abstract][Full Text] [Related]
12. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
Krauwinkel W; Dickinson J; Schaddelee M; Meijer J; Tretter R; van de Wetering J; Strabach G; van Gelderen M
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):43-52. PubMed ID: 23728524
[TBL] [Abstract][Full Text] [Related]
13. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
Malik M; van Gelderen EM; Lee JH; Kowalski DL; Yen M; Goldwater R; Mujais SK; Schaddelee MP; de Koning P; Kaibara A; Moy SS; Keirns JJ
Clin Pharmacol Ther; 2012 Dec; 92(6):696-706. PubMed ID: 23149929
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL).
Michel MC; Chapple CR
Eur Urol; 2006 Mar; 49(3):501-8; discussion 508-9. PubMed ID: 16442211
[TBL] [Abstract][Full Text] [Related]
15. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
16. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
Eltink C; Lee J; Schaddelee M; Zhang W; Kerbusch V; Meijer J; van Marle S; Grunenberg N; Kowalski D; Drogendijk T; Moy S; Iitsuka H; van Gelderen M; Matsushima H; Sawamoto T
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):838-50. PubMed ID: 22943933
[TBL] [Abstract][Full Text] [Related]
17. The effect of udenafil on the hemodynamics of healthy male volunteers administered tamsulosin.
Kim MG; Kim JR; Kim BH; Lim KS; Shin SG; Jang IJ; Yu KS; Cho JY
Curr Med Res Opin; 2013 Jun; 29(6):685-93. PubMed ID: 23557068
[TBL] [Abstract][Full Text] [Related]
18. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.
Iitsuka H; Tokuno T; Amada Y; Matsushima H; Katashima M; Sawamoto T; Takusagawa S; van Gelderen M; Tanaka T; Miyahara H
Clin Drug Investig; 2014 Jan; 34(1):27-35. PubMed ID: 24178236
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.
Groen-Wijnberg M; van Dijk J; Krauwinkel W; Kerbusch V; Meijer J; Tretter R; Zhang W; van Gelderen M
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):417-429. PubMed ID: 27350625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
